Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T L Timme

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Molecular Endocrinology (Baltimore, Md.)|April 1, 1991
Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progressionV W Merz, G J Miller, T Krebs, et al.
Expert Opinion on Biological Therapy|December 1, 2001
In situ gene therapy for prostate cancer: immunomodulatory approachesT C Thompson, T L Timme, S Ebara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1996
Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical studyR H Williams, A M Stapleton, G Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1995
Association of p53 mutations with metastatic prostate cancerJ A Eastham, A M Stapleton, A E Gousse, et al.
International Journal of Cancer|January 27, 1995
DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancerD R Greene, S R Taylor, M Aihara, et al.
Human Gene Therapy|May 26, 1999
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trialJ R Herman, H L Adler, E Aguilar-Cordova, et al.
Cancer Research|November 15, 1995
In vivo gene therapy with p53 or p21 adenovirus for prostate cancerJ A Eastham, S J Hall, I Sehgal, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancerY Nasu, C H Bangma, G W Hull, et al.
Gene Therapy|August 6, 1999
Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic modelY Nasu, C H Bangma, G W Hull, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastasesA M Stapleton, T L Timme, A E Gousse, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Molecular Endocrinology (Baltimore, Md.)|April 1, 1991
Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progressionV W Merz, G J Miller, T Krebs, et al.
Expert Opinion on Biological Therapy|December 1, 2001
In situ gene therapy for prostate cancer: immunomodulatory approachesT C Thompson, T L Timme, S Ebara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1996
Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical studyR H Williams, A M Stapleton, G Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 1995
Association of p53 mutations with metastatic prostate cancerJ A Eastham, A M Stapleton, A E Gousse, et al.
International Journal of Cancer|January 27, 1995
DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancerD R Greene, S R Taylor, M Aihara, et al.
Human Gene Therapy|May 26, 1999
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trialJ R Herman, H L Adler, E Aguilar-Cordova, et al.
Cancer Research|November 15, 1995
In vivo gene therapy with p53 or p21 adenovirus for prostate cancerJ A Eastham, S J Hall, I Sehgal, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancerY Nasu, C H Bangma, G W Hull, et al.
Gene Therapy|August 6, 1999
Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic modelY Nasu, C H Bangma, G W Hull, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastasesA M Stapleton, T L Timme, A E Gousse, et al.
Pageof 6